netFormulary NHS
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust
 Search
 Results

Looking for Adalimumab found 31 matches

Formulary items 3 matches
   
Open monograph to display formulary status BNF Category
  Adalimumab
(See 10.01.03 for preparations)
Gastro-intestinal system - Cytokine inhibitors - 01.05.03
  Adalimumab Skin - Drugs affecting the immune response - 13.05.03
  Adalimumab  (Amgevita(biosimilar) or Humira) Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in subsection NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab (10.01.03)
link in subsection NICE TA143: Ankylosing spondylitis - adalimumab, etanercept and infliximab (10.01.03)
link in drug section NICE TA146: Adalimumab for the treatment of adults with psoriasis (10.01.03)
link in drug section NICE TA146: Psoriasis - adalimumab (13.05.03)
link in drug section NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40) (01.05.03)
link in drug section NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)  (01.05.03)
link in drug section NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in subsection NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy (01.05.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa (13.05.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (10.01.03)
link in drug section NICE TA455 Adalimumab, etanercept and usterkinumab for treating plaque psoriasis in childen and young people (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)


 

netFormulary